Cruz et al. report that variants of TNF receptor 1 (TNFR1) found in patients with systemic juvenile idiopathic arthritis induce an inflammatory phenotype caused by cellular stress through dysfunction of multiple cellular trafficking pathways. The cover image shows super-resolution microscopy of an HT1080 cell harboring a variant of TNFR1, K203X (green), that preferentially sequesters intracellularly to the Golgi complex (red). The nucleus is stained with Hoechst 33342 (blue). Image credit: Davide Randazzo.
BACKGROUND. Molecular subtyping may offer a promising path toward a unified framework for precision oncology. We sought to characterize the patterns of programmed cell death (PCD), a pivotal cellular process shaping both intrinsic tumor malignancy and the tumor microenvironment, to better understand tumor heterogeneity. METHODS. We performed integrative multi-cohort transcriptomic analyses encompassing four canonical PCD modes across multiple cancer types. We identified PCD subtypes using nonnegative matrix factorization (NMF), characterized their molecular features and clinical relevance, and developed a streamlined 20-gene classifier to facilitate subtype assignment. RESULTS. We identified five conserved PCD subtypes with distinct genomic alterations, cellular stresses, malignant traits, prognostic outcomes, and immune landscapes. In the immunotherapy setting, PCD subtypes were associated with distinct outcomes across multiple cancer types, with the pyroptosis-dominant (PCD-P) subtype showing the most favorable outcomes. The 20-gene classifier showed good discriminatory performance across independent cohorts. Finally, we proposed candidate subtype-specific therapeutic strategies. CONCLUSION. This study establishes a comprehensive framework for characterizing PCD patterns in cancer, laying the groundwork for biomarker discovery and rational therapeutic design that warrant future evaluation of efficacy and toxicity. FUNDING. National Key R&D Program of China; National Natural Science Foundation of China; Fundamental Research Funds for the Central Universities, Sun Yat-sen University; HE Science Foundation; Young Talents Program of Sun Yat-sen University Cancer Center; Academician Workstation of Jun Ma; Specific Research Fund of the Innovation Platform for Academicians of Hainan Province; Shenzhen Medical Research Fund; Guangdong Basic and Applied Basic Research Foundation.
Zi-Wei Huang, Zi-Han Wang, Yi Liu, Jia-Yi Shen, Yan-Ling Wu, Zi-An Fang, Dong-Hong Wu, Yi-Zhe Cheng, Jing-Jing Zhang, Xiong Zou, Jun Ma, Jiawei Lv, Shuang Wang, Yu-Pei Chen
Ibrutinib, a Bruton's tyrosine kinase inhibitor, is indicated for treating chronic lymphocytic leukemia (CLL), but hypertension is a common cardiovascular adverse event. Previous studies have linked ibrutinib to cardiac events through dysregulated intracellular calcium handling, but the mechanisms underlying ibrutinib-associated hypertension remain largely unknown. Here, we followed up 225 CLL patients receiving ibrutinib or managed with watch-and-wait strategy, and identified ibrutinib as an independent risk factor for hypertension. In mice, ibrutinib elevated arterial blood pressure (BP) without structural remodeling of small arteries, and it potentiated K+-induced vasoconstriction. In vascular smooth muscle cells (VSMCs), ibrutinib upregulated CaV1.2 channel expression and function, as evidenced by enhanced CaV1.2 currents and K+-triggered-[Ca2+]i elevation. Mechanistically, ibrutinib suppressed casein kinase 2 (CK2)-mediated HSP90β phosphorylation, and stabilized C/EBP-β, which bound to the promoter of Cacna1c gene and drove CaV1.2 transcription. Significantly, C/EBP-β knockdown attenuated ibrutinib-induced CaV1.2 hyperactivity and vasoconstriction. Collectively, these findings reveal a CK2-HSP90β-C/EBP-β-CaV1.2 signaling cascade through which ibrutinib enhances vascular Ca2+ influx and vasoconstriction, thereby elevating arterial BP. Thus, this study nominates C/EBP-β as a therapeutic target for ibrutinib-associated hypertension.
Ludan Zhang, Shumin Yin, Wei Hou, Dan Yang, Yiyuan Jia, Yun Liu, Yan Wang, Sirui Zhao, Xiaoyan Gao, Xiaolin Sun, Xiao Lu, Jianyong Li, Ming Chu, Xiaoqing Xiong, Huayuan Zhu, Juejin Wang
BACKGROUND. Alport syndrome (AS), a Mendelian kidney disease, is caused by pathogenic mutations in the X- linked gene COL4A5 and autosomal genes COL4A3, COL4A4 encoding the alpha-chains secreted by podocytes to form the glomerular basement membrane collagen α3α4α5(IV) trimer. Nonsense mutations in autosomal recessive and hemizygous X-linked Alport syndrome (NMAS) introduce premature termination codons and have a particularly poor prognosis, with kidney failure typically occurring by early adulthood. There is substantial unmet need for effective therapy for AS, which has no approved treatments. Exaluren (formerly ELX-02) is a novel eukaryotic ribosome-targeted glycoside that is preferentially taken up by kidney cells and promotes readthrough of premature but not native termination codons, allowing full-length protein production. METHODS. In this proof-of-mechanism study, three patients (ages 12–18) with autosomal recessive Alport syndrome and a COL4A4 premature termination codon received daily subcutaneous exaluren (0.75 mg/kg) for 8 weeks. RESULTS. Safety and tolerability assessments (primary endpoint) revealed no new signals. Secondary endpoints assessed by kidney biopsy before and after treatment revealed increased collagen α3(IV), α4(IV) and α5(IV) abundance, physiologically localised collagen α5(IV), and partially improved podocyte morphology in all participants, with changes directionally concordant with increased collagen α3α4(IV) abundance. Proteinuria changes were inconsistent with interpretation limited by intra-patient variability and the short treatment duration; hematuria persisted in all participants. CONCLUSION. These findings provide first-in-human evidence of exaluren-mediated collagen IV readthrough and justify further trials in Alport syndrome and other nonsense mutation-driven kidney diseases, which often cause early-onset kidney failure. TRIAL REGISTRATION. ClinicalTrials.gov Identifier: NCT05448755.
Daniel P. Gale, Detlef Böckenhauer, Maryline Fresquet, Emily Williams, Conor J. Sugden, Melanie M.Y. Chan, Katie Wong, Meei-Hua Lin, Kohei Omachi, Konstantinos Tzoumkas, Lior Horonchik, Roger B. Clark, Jochen Reiser, Peter Mundel, Uwe Andag, Jeffrey H. Miner, Rachel Lennon, Nicole Endlich, Behzad Najafian, Sumit Aggarwal
Fibrosis is a common outcome of chronic tissue injury, yet immune regulators that are conserved across species and translatable to human disease remain poorly defined. By integrating human kidney transcriptomes with multiple murine models of kidney fibrosis, we identified the ETS transcription factor ELF4 as a conserved, immune-enriched regulator associated with disease severity. ELF4 expression was highest in natural killer (NK) cells. Genetic deletion of Elf4, including NK cell–specific ablation, attenuated experimental kidney injury, with reduced inflammation, fibrosis, and loss of renal function. Single-cell and functional analyses showed that ELF4 deficiency disrupts late-stage NK cell maturation and broadly suppresses cytotoxic and interferon-γ (IFNγ) effector programs. Mechanistically, ELF4 directly sustains STAT1 transcription, maintaining a STAT1–TBX21 program required for NK cell maturation and effector competence. Consistent with this framework, NK cell depletion, IFNγ neutralization, or antisense-mediated suppression of Elf4 phenocopied renal protection. Together, these findings identify ELF4 as a transcriptional licensing factor that links NK cell state to kidney injury and highlight innate immune programming as a potential therapeutic entry point in chronic kidney disease.
Shen Li, Hailong Hu, Zachary R. Lanzar, Xiangchen Gu, Elisa Cruz-Morales, Audrey C. Bochi-Layec, Andrea Sanchez-Navarro, Jihwan Park, Rojesh Shrestha, Hongbo Liu, Aaron J. Donner, Meei-Hua Lin, Thomas A. Bell, Jeffrey H. Miner, Marco Ruella, Eric Vivier, Carrie L. Lucas, Christopher A. Hunter, Katalin Susztak
Epigenetic modifications contribute to lipid-related disorders by modulating the expression of key genes involved in lipid metabolism. Accumulating evidence suggests that lipid metabolism-mediated ferroptosis drives the progression of metabolic associated steatohepatitis (MASH) and liver injury. However, whether epigenetic mechanisms remodel lipid metabolism to regulate ferroptosis-induced liver damage remains unclear. Here, through pharmacological screening of epigenetics-related compounds and CRISPR-Cas9-based screening targeting epigenetic factors, we identified DOT1 Like Histone Lysine Methyltransferase (DOT1L) as a key sensitizer of hepatocytes to ferroptosis and subsequent liver injury, whereas inhibition of DOT1L reverses the phenomenon. DOT1L loss remodeled the phospholipid landscape by decreasing PUFA-containing phospholipids while increasing monounsaturated and lysophospholipid species. Mechanistically, DOT1L depletion reduced H3K79me1 and H3K79me2 occupancy at the PLA2G7, ALDH3B1, and PLCXD3 loci, particularly across gene-body regions, while increasing promoter-proximal accessibility and expression of these phospholipid-remodeling genes. These genes suppress ferroptosis by reducing the levels of phospholipids containing polyunsaturated fatty acids (PL-PUFAs). Furthermore, we demonstrated that AMPK phosphorylates DOT1L at Ser786, weakens its association with AF9, and suppresses H3K79 methyltransferase activity and ferroptosis sensitivity. Collectively, our findings reveal the AMPK–DOT1L–H3K79 methylation axis as a novel lipid metabolic pathway that regulates ferroptosis and maintains hepatic homeostasis, offering new therapeutic insights for ferroptosis-related liver injury.
Jia-ming Hu, Shuo Liu, Zheng-ze Pan, Yi-jia Gao, Wei-wei Cui, Xiao Zhuang, Rong Wang, Ya-jing Han, Jia-xing Liu, Xiang-chuang Fan, Dan-dan Song, Zi-yang Zhang, Wan-yang Sun, Zong-li Zhang, Rong-rong He, Yun-fei Xu, Wei Gu, Chang Pan, Bo Chu
Breast cancer is the most common cancer in women worldwide, with more than 2 million women diagnosed each year. This series of reviews, curated by Dr. Rinath Jeselsohn, highlights recent breakthroughs in therapeutic development that are changing the outlook for breast cancer patients, including improvements in immunotherapy, antibody-drug conjugates, endocrine therapies, and kinase inhibitors.
×
In this episode, Sai Prasad Pydi, Simran Singh, and Ashish Kumar describe how obesity-associated inflammation impairs pancreatic β cell function, yet the mechanisms by which immune cells acutely regulate insulin secretion remain poorly defined...